Teva Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Teva Pharma (TEVA) Tops Q2 EPS by 2c, Affirms Outlook
August 5, 2020 7:02 AM EDTTeva Pharma (NYSE: TEVA) reported Q2 EPS of $0.55, $0.02 better than the analyst estimate of $0.53. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $3.93 billion.
GUIDANCE:
Teva Pharma sees FY2020 EPS of $2.30-$2.55, versus the consensus... More
